Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

U.S. must address IP and market access barriers abroad to protect American innovation

By Ernest Kawka  |    January 31, 2023
PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine...   Read More

Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

By Douglas Petersen  |    January 17, 2023
Last summer, the United States and Taiwan launched the U.S.-Taiwan Initiative on 21st-Century Trade to deepen economic and trade relations. In detailed comments to the U.S. Trade Representative...   Read More

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

By Megan Van Etten  |    November 17, 2022
The United States has led the charge in the development of vaccines and treatments to combat COVID-19 thanks in large part to our robust innovation ecosystem, supported by intellectual property (IP)...   Read More

Six ways I-MAK is lying about biopharma patents

By Megan Van Etten  |    November 16, 2022
The Arnold-Venture funded advocacy group Initiative for Medicines, Access & Knowledge, Inc. (or I-MAK) is on a global media tour, espousing their point of view on the patent system. Some experts and...   Read More

TRIPS waiver expansion risks public health

By Megan Van Etten  |    November 14, 2022
The Biden administration and other World Trade Organization members are considering expanding the harmful and unnecessary waiver of intellectual property (IP) protections under the Agreement on...   Read More

Expanding the WTO intellectual property waiver will hurt American jobs

By Megan Van Etten  |    November 9, 2022
The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was...   Read More

PhRMA submission to USTR calls for urgent defense of American innovation abroad

By Douglas Petersen  |    November 1, 2022
The United States leads the world in medicine research, development and manufacturing, and international trade delivers those medicines to patients around the globe. But trade barriers imposed in...   Read More

The law driving technology transfer and fostering innovation

By Megan Van Etten  |    October 24, 2022
The bipartisan Bayh-Dole Act created a framework for researchers receiving federal funds to patent and license their inventions to companies for further development and commercialization. This...   Read More

Don’t take anti-innovation, activist funded academics at their word

By Jocelyn Ulrich  |    October 18, 2022
It’s disappointing to see yet more studies published by activist-funded industry critics that fail to recognize the nature of competition in the biopharmaceutical market and use cherry-picked data to...   Read More

New report ignores benefits of patent system to innovation and patients

By Megan Van Etten  |    September 30, 2022
A recent report from the Initiative for Medicines, Access & Knowledge – known as I-MAK – highlights fundamental misunderstandings about America’s patent system and how it benefits patients and...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates